Page 3 - Ohnson Johnson News Today

Sen. Bernie Sanders is once again taking the pharmaceutical industry to task, issuing a report Tuesday that highlights the cost of three blockbuster drugs that are far pricier in the US than in other countries.

A new report released Tuesday by Sen. Bernie Sanders (I-Vt.) takes aim at the prices and executive compensation of three major drug manufacturers, previewing his lines of attack for when the companies’ CEOs appear at a hearing later this week. In the report prepared by Democratic staff on the Senate Health, Education, Labor and Pensions…

It's going to take a lot to interrupt these companies' streaks.

Since taking the helm of the committee that oversees the nation’s health care system last year, Senator Bernie Sanders has used his perch to take aim at pharmaceutical executives over the cost of prescription drugs. Next week, the CEOs of drug manufacturers Johnson & Johnson, Merck, and Bristol Myers Squibb will appear before the Health, Education, Labor and Pensions Committee to testify at a hearing concerned with the high prices of prescription medication in the United States as co...

These industry-leading, time-tested companies are ideal for retired investors.

The CEOs of Johnson & Johnson and Merck have agreed to testify at a Senate hearing in February about prescription drug prices and will not face a subpoena, Sen. Bernie Sanders (I-Vt.) said Friday. The Senate Health, Education, Labor and Pensions (HELP) Committee hearing will take place on Feb. 8. Johnson & Johnson CEO Joaquin Duato,…

Johnson & Johnson (NYSE:JNJ) Q4 2023 Earnings Call Transcript January 23, 2024 Johnson & Johnson beats earnings expectations. Reported EPS is $2.29, expectations were $2.27. Johnson & Johnson isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to […]

Sen. Bernie Sanders (I-Vt.) said his committee will hold a vote next week on whether to subpoena some of the country’s top pharmaceutical CEOs to testify about drug prices.

Sen. Bernie Sanders (I-Vt.) said he is confident that forcing drug company CEOs to testify about high prices can result in meaningful changes. Less than a week ahead of a planned vote to subpoena the CEOs of Johnson & Johnson and Merck, the chair of the Senate Health, Education, Labor and Pensions Committee said having…

(Reuters) -Johnson & Johnson on Tuesday reported quarterly results just above Wall Street expectations, helped by strong sales of its blockbuster psoriasis drug Stelara, which is expected to face fresh U.S. competition from biosimilar versions next year. A key patent for Stelara expired in the United States last year, but J&J struck deals with competitors to delay the launches of their biosimilars until 2025. Analysts have said the delay in biosimilar launches would make Stelara a l...